Latest Share Chat

SUMM.L Share News (SUMM)

SUMM.L Information

There is currently no data for SUMM

Summit Therapeutics surges on positive clinical trial update

Mon, 17th Aug 2015 12:33

(ShareCast News) - Shares in Summit Therapeutics surged after the company said that its phase 1B clinical trial of SMT C1100 for the treatment of Duchenne muscular dystrophy met its primary objective and will now move on to a Phase 2 trial.The drug discovery and development company said half of the patients who received the higher dose of SMT C1100 achieved the desired plasma levels while following specific dietary guidance.Initial analysis showed six of 12 patients achieved the desired plasma level after receiving a 2,500 mg dose of SMT C1100 twice daily for 14 days. In a prior Phase 1b trial, only two of 12 patients dosed with SMT C1100 achieved the desired plasma level.Summit said SMT C1100 was well tolerated at all doses tested with no serious adverse events reported.The company said it plans to start the Phase 2 open-label trial in the fourth quarter of this year to evaluate the longer-term benefits of the drug on muscle health, function and safety.Summit's chief executive officer, Glyn Edwards, said: "These data clear an important hurdle in the development of SMT C1100 by demonstrating it is a viable drug candidate to bring proof-of-concept for the Company's burgeoning utrophin modulator pipeline and more importantly, hope to all patients and their families living with this devastating disease."Our priority is advancing SMT C1100 efficiently through future patient clinical trials designed to evaluate the potential clinical benefit of this promising treatment, and this will start with an open-label Phase 2 trial that is expected to start by the end of this year."At 1247 BST, Summit shares were up 9.6% at 172.60p.

More News

15 Dec 2016 12:38

Summit Therapeutics widens loss as drug development continues

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its financial results for the third quarter to 31 October on Thursday. The AIM-traded firm had cash and cash equivalents at period end of £34.6m compared to £16.3m on 31 January. Its loss for the nine months was £1

16 Nov 2016 12:28

Summit Therapeutics enrols first US patients in ezutromid trial for DMD

(ShareCast News) - AIM-listed drug discovery and development company Summit Therapeutics has enrolled its first patients in phase II proof of concept trials in the US of ezutromid in patients with Duchenne muscular dystrophy. Summit said enrolment and dosing of patients into Phase Out DMD in the UK

6 Oct 2016 14:28

Summit Therapeutics shares plummet despite positive progress

(ShareCast News) - Drug discovery and development company Summit Therapeutics presented preclinical data at the 21st International Congress of the World Muscle Society in Granada, Spain on Thursday, including further findings from its programme to develop tools to measure biomarkers of muscle health

4 Oct 2016 11:52

BUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal

** Shares in drug developer Summit Therapeutics up 58 pct after teams up with US drug co Sarepta Therapeutics to develop and market DMD drug in Europe ** Stock poised for its best day since April 2009 ** Co gets $40 mln upfront payment, could receive up to $522 million in milestone p

9 Aug 2016 11:51

Summit Therapeutics Sees Positive Phase I Trial Results For Ezutromid

21 Jun 2016 06:46

Summit Therapeutics Shows Further Positive Trial Data For Ridinilazole

17 Jun 2016 11:21

Summit Therapeutics Enrols First Patient In Phase II Ezutromid Trial

2 Jun 2016 14:30

Cash reduced, losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its first quarter results on Thursday, with cash reduced and losses widening. The AIM-traded firm, which is advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), had cash and ca

10 May 2016 16:46

Losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics reported an increase in cash and activities in its full-year results on Tuesday, though its losses widened as it carried its projects towards commercialisation. The AIM-traded firm had cash and cash equivalents of £16.3m o

10 May 2016 11:20

Summit Therapeutics Posts Widened Loss As It Progresses Programmes

28 Apr 2016 11:11

Summit Therapeutics Gets Further US Patent For Antibiotic Ridinlazole

26 Apr 2016 11:16

Summit Therapeutics Gets Clearance To Expand Ezutromid Trial To US

30 Mar 2016 12:48

Summit reports positive results from Duchenne muscular dystrophy treatment

(ShareCast News) - Summit Therapeutics reported positive interim findings on Wednesday, from a recent Phase 1 trial of a new oral formulation of its SMT C1100 therapy for Duchenne muscular dystrophy. The AIM-traded drug discovery and development company focuses on advancing therapies for Duchenne mu

30 Mar 2016 11:06

Summit Therapeutics Gets Positive Interim SMT C1100 Test Results

7 Mar 2016 12:43

Latest Share Chat

SUMM.L Share News (SUMM)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Summit Therapeutics surges on positive clinical trial update

Login to your account

Quickpicks are a member only feature

Login to your account